Sponsor content
330 result(s) found, displaying 51 to 60
-
Australian public assessment report (AusPar)Enhertu (trastuzumab deruxtecan) was approved to treat adult patients with unresectable or metastatic HER2-low breast cancer.
-
Australian public assessment report (AusPar)Sidapvia (dapagliflozin+sitagliptin), a new drug combination, has been approved to treat type 2 diabetes mellitus in adults, as an adjunct to diet and exercise to improve glycaemic control.
-
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Pulmicort 0.5 mg/ml nebuliser suspension.
-
Australian public assessment report (AusPar)Lynparza (olaparib) has been approved for the treatment of BRCA-mutated HER2-negative high risk early breast cancer and metastatic castration-resistant prostate cancer.
-
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Pulmicort Respules Budesonide Suspension for Inhalation 2ml: 1mg.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Pulmicort Respules Budesonide Suspension for Inhalation 2ml: 0.5mg.
-
Cancellation by sponsorRequested by AstraZeneca Pty Ltd
-
Cancellation by sponsorRequested by AstraZeneca Pty Ltd